Journal Mobile Options
Table of Contents
Vol. 66, No. 3, 2004
Issue release date: June 2004
Oncology 2004;66:167–179
(DOI:10.1159/000077991)

A Review and Update on Cholangiocarcinoma

Olnes M.J. · Erlich R.
aDepartment of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, and bDivision of Hematology-Oncology, Department of Medicine, Alvin and Lois Lapidus Cancer Institute, Sinai Hospital of Baltimore, Baltimore, Md., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Cholangiocarcinoma is a malignant neoplasm arising from the biliary epithelium that was first described by Durand-Fardel in 1840. Today, it continues to defy diagnosis and treatment. It is difficult to diagnose in part because of its relative rarity, and because it is clinically silent until it becomes advanced disease with obstructive symptoms. The worldwide incidence of cholangiocarcinoma has risen over the past three decades. There is marked geographic variability in the prevalence of this disease, due in large part to regional environmental risk factors. Surgical resection remains the only curative treatment, and high priorities are improving diagnostic methods, and clinical staging for resection once the disease is suspected. A recent trend towards aggressive surgical management has improved outcomes. Chemotherapy, palliative stenting, and radiation are reserved for patients who are not resectable, those with recurrence after surgery, and those who decline surgical intervention. Recent trials using combination systemic chemotherapy and neoadjuvant chemoradiation are promising, but require further study. Over the past five years, several important studies have yielded new insights into the molecular mechanisms of cholangiocarcinoma tumorigenesis. In this review we discuss epidemiology, etiologic factors, molecular pathogenesis, diagnosis, staging, and treatment of cholangiocarcinoma. Particular focus is on recent studies into the cellular and molecular pathogenesis of the disease, recent chemotherapy trials, and newer methods of staging and screening for this devastating malignancy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, Wilson SD, Demeure MJ, Rilling WS, Dua KS, Pitt HA: Improved survival in resected biliary malignancies. Surgery 2002;132:555–563.
  2. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar cholangiocarcinoma: Patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998;228:385–394.
  3. Meyer CG, Penn I, James L: Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000;69:1633–1637.
  4. Hejna M, Pruckmayer M, Raderer M: The role of chemotherapy and radiation in the management of biliary cancer: A review of the literature. Eur J Cancer 1998;34:977–986.

    External Resources

  5. Todoroki T: Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 2000;47:644–649.
  6. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;54:965–969.
  7. Kubicka S, Rudolf KL, Tietze MK, Lorenz M, Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001;48:783–789.
  8. Colleoni M, Di Bartolomeo M, Di Leo A, Zilembo N, Carnaghi C, Pandolfi A, Rimassa L, Artale S, Bajetta E: Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. Eur J Oncol 1995;31A:2427–2428.
  9. Harvey JH, Smith FP, Schein PS: 5-fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984;2:1245–1248.
  10. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE: A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998;82:2321–2325.
  11. Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C: Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996;14:2311–2315.
  12. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999;56:177–180.
  13. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH: Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000;23:425–428.
  14. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful in gallbladder carcinoma? Cancer 2002;95:1685–1695.
  15. Cantore M, Rabbi C, Guadagni S, Zamagni D, Aitini E: Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma. Ann Oncol 2002;12:1687–1688.

    External Resources

  16. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemoe KD, Cameron JL: Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788–797.
  17. McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, Curley SA: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605–609.
  18. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ: Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000;6:309–316.
  19. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, Sorrell M, Tempero M, Langnas A: Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Translplant 2002;2:774–779.
  20. Nordback IH, Pitt HA, Coleman J, Venbrux AC, Dooley WC, Yeu NN, Cameron JL: Unresectable hilar cholangiocarcinoma: Percutaneous versus operative palliation. Surgery 1994;115:597–603.
  21. Ortner M: Photodynamic therapy for cholangiocarcinoma. J Hepato-Biliary-Pancreatic Surg 2001;8:137–139.
  22. Ortner M, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, Müller J, Hortnagl H, Lochs H: Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998;114:536–542.
  23. Zoepf T, Jakobs R, Rosenbaum A, Apel D, Arnold JC, Riemann JF: Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001;54:763–766.
  24. Rumalla A, Baron TH: Evaluation and endoscopic palliation of cholangiocarcinoma. Dig Dis 1999;17:194–200.
  25. De Palma GD, Galloro G, Siciliano S, Iovino P, Catanzano C: Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: Results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001;53:547–553.
  26. Nimura Y: Extended surgery in bilio-pancreatic cancer: The Japanese experience. Semin Oncol 2002;29:17–22.
  27. Klempnauer J, Ridder JG, Werner M, Weimann A, Pichlmayr R: What constitutes long term survival after surgery for hilar cholangiocarcinoma? Cancer 1997;79:26–34.
  28. Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M: Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;5:663–671.

    External Resources

  29. Jarnagin WR: Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000;19:156–176.
  30. Longmire WP, McArthur MS, Bastoumis EA, Hiatt J: Carcinoma of the extrahepatic biliary tract. Ann Surg 1973;173:333–343.
  31. Martin RC 2nd, Fong Y, DeMatteo RP, Brown K, Blumgart LH, Jarnagin WR: Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma. J Am Coll Surg 2001;193:620–625.
  32. Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR: Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 2002;235:392–399.
  33. Tamada K, Ueno N, Ichiyama M, Tomiyama T, Nishizono T, Wada S, Oohashi A, Tano S, Ido K, Kimura K: Assessment of pancreatic parenchymal invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1996;28:492–496.
  34. Tamada K, Ido K, Ueno N, Ichiyama M, Nishizono T, Wada S, Noda T, Tano S, Aizawa T, et al: Assessment of portal vein invasion by bile duct cancer using intraductal ultrasonography. Endoscopy 1995;27:573–578.
  35. Tamada K, Ido K, Ueno N, Ichiyama M, Nishizono T, Wada S, Noda T, Tano S, Aizawa T, et al: Assessment of the course and variations of the hepatic artery in bile duct cancer by intraductal ultrasonography. Gastrointest Endosc 1996;44:249–256.
  36. Kluge R, Schmidt F, Cac K, Barthel H, Hesse S, Georgi P, Seese A, Huster D, Berr F: Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001;33:1029–1035.
  37. Pichlmayr R, Lamesch P, Weimann A, Tusch G, Ringe B: Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83–88.
  38. AJCC (American Joint Committee on Cancer): Cancer Staging Manual, ed 6, Greene FL, Page DL, Fleming ID (eds). New York, Springer, 2002.
  39. Bismuth H, Corlette MB: Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975;140:170–176.
  40. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–475.
  41. Klatskin G: Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965;38:241–256.
  42. Albores-Saavedra J, Henson DE, Sorbin LH: Histological typing of tumours of the gallbladder and extrahepatic bile ducts, ed 2. Berlin, Springer, 1991.
  43. Farrell RJ, Agarwal B, Brandwein SL, Underhill J, Chuttani R, Pleskow DK: Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 2002;56:681–687.
  44. Lee SS, Kim MH, Lee SK, Kim TK, Seo DW, Park JS, Hwang CY, Chang HS, Min YI: MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc 2002;56:25–32.
  45. Magnuson TH, Bender JS, Duncan MD, Ahrendt SA, Harmon JW, Regan F: Utility of magnetic resonance cholangiography in the evaluation of biliary obstruction. J Am Coll Surg 1999;1:63–71.
  46. Wiersema MJ, Vilmann P, Giovannini M, Chang KJ, Wiersema LM: Endosonography-guided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment. Gastroenterology 1997;112:1087–1095.
  47. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH: Detection of primary hepatic malignancy in liver transplant candidates: Prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533–542.
  48. Yamashita Y, Takahashi M, Kanazawa S, Charnsangavej C, Wallace S: Parenchymal changes of the liver in cholangiocarcinoma: CT evaluation. Gastrointest Radiol 1992;17:161–166.
  49. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WMC, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H: Guidelines for the diagnosis and treatment of cholangiocarcinoma: Consensus document. Gut 2002;51(suppl VI): vi1–vi9.
  50. Chen CY, Shiesh SC, Tsao HC, Lin XZ: The assessment of biliary CA 125, CA 19-9, and CEA in diagnosing cholangiocarcinoma – The influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002;49:616–620.
  51. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GF: The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204–207.
  52. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H: Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 2000;31:247–248.
  53. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroentrology 1995;108:865–869.
  54. Washburn WK, Lewis WD, Jenkins RL: Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995;130:270–276.
  55. Pitt HA, Dooley WC, Yeo CJ, Cameron JL: Malignancies of the biliary tree. Curr Probl Surg 1995;32:1–90.
  56. Sons HU, Borchard F: Carcinoma of the extrahepatic bile ducts: A post-mortem study of 65 cases and review of the literature. J Surg Oncol 1987;34:6–12.
  57. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184–190.
  58. Satarun S, Haswell-Elkins MR, Tsuda M, Mairiang P, Sithithaworn P, Mairiang E, Esumi H, Sukprasert S, Yongvanit P, Elkins DB: Thiocyanate-independent nitrosation in humans with carcinogenic parasite infection. Carcinogenesis 1996;17:1075–1081.
  59. Lai G-H, Zhang Z, Sirica AE: Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with Emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Therapeut 2003;2:265–271.
  60. Vickers SM, Jhala NC, Ahn E-Y, McDonald JM, Pan G, Bland KI: Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-γ). Ann Surg 2002;235:872–878.
  61. Ahn E-Y, Pan G, Vickers SM, McDonald JM: IFN-γ upregulates apoptosis-related molecules and enhances FAS-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 2002;100:445–451.
  62. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ: COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002;35:552–559.
  63. Okaro AC, Deery AR, Hutchins RR, Davidson BR: The expression of anti- apoptotic proteins Bcl-2, Bcl-X, Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 2001;54:927–932.
  64. Sirica AE, Li GH, Endo K, Zhang Z, Yoon BI: Cyclooxygenase-2 and erb-2 in cholangiocarcinoma: Potential therapeutic targets. Semin Liver Dis 2002;22:303–313, 2002.
  65. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ: Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985–993.
  66. Wu GS, Zou SQ, Luo XW, Wu JH, Liu ZR: Proliferative activity of bile from congenital choledochal cyst patients. World J Gastroenterol 2003;9:184–187.
  67. Endo K, Yoon B-I, Pairojkul C, Demetris AJ, Sirica AE: ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;439–450.
  68. Ukita Y, Kato M, Terada T: Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, immunohistochemistry. J Hepatol 2002;36:780–785.
  69. Ito Y, Miyoshi E, Takeda T, Sakon M, Tsujimoto M, Yokosaki Y, Monden M, Matsuura N: Ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. Oncology 2000;58:248–252.
  70. Chariyalertsak S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Fürstenberger G, Marks F, Müller-Decker K: Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2000;48:80–86.

    External Resources

  71. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002;40:269–278.
  72. Sirica AE, Lai G-H, Zhang Z: Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 2001;16:363–372.
  73. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T: Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045–3054.
  74. Kang KK, Kim WH, Jang JJ: Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Human Pathol 2002;877–883.
  75. Benckert C, Jonas S, Cramer T, Marschall ZV, Schafer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, Hocker M, Rosewicz S: Transforming growth factor β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003;63:1083–1092.
  76. Sugimachi K, Taguchi K-I, Aishima S-I, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M: Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001;14:900–905.
  77. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ: Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633–639.
  78. Taniai M, Higuchi H, Burgart LJ, Gores GJ: P16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002;123:1090–1098.
  79. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, Uhlmann D, Hauss J, Wittekind C: Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624–631.
  80. Lee S, Kim WH, Jung H-Y, Yang MH, Kang GH: Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002;161:1015–1022.

    External Resources

  81. Limpaiboon T, Krissadarak K, Sripa B, Jearanaikoon P, Vajarabhongsa B, Chau-in S, Amornrat R, Pairojkul C: Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with a poor prognosis. Cancer Lett 2002;181:215–222.
  82. Liu D, Momoi H, Li L, Ishikawa Y, Fukumoto M: Microsatellite instability in thorotrast-induced human intrahepatic cholangiocarcinoma. Int J Cancer 2002;102:366–371.
  83. Kamikawa T, Amenomori M, Itoh T, Momoi H, Hiai H, Machinami R, Ishikawa Y, Mori Y, Shimahara Y, Yamoaka Y, Fukumoto M: Analysis of genetic changes in intrahepatic cholangiocarcinoma induced by thorotrast. Radiat Res 1999;152:S118–124.
  84. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI: Mutations of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999;79:477–483.
  85. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A: p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. Hepatology 1995;22:774–779.
  86. Rashid A, Ueki T, Gao Y-T, Houlihan PS, Wallace C, Wang B-S, Shen M-C, Deng J, Hsing AW: K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: A population-based study in China. Clin Cancer Res 2002;8:3156–3163.
  87. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, Muto Y, Furukawa M: Analysis of microsatellite instability, K-ras mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002;49:604–608.
  88. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K, et al: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: Relation to gross tumor morphology. Gastroenterology 1995;109:1612–1617.
  89. Bertazzi PA, Consonni D, Bachetti S, Rubagotti M, Baccarelli A, Zocchetti C, Pesatori AC: Health effects of dioxin exposure: A 20-year mortality study. Am J Epidemiol 2001;153:1031–1044.
  90. Yen S, Hsieh CC, Macmahon B: Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use. Cancer 1987:59:2112–2116.
  91. Lowenfelds AB, Norman J: Isoniazid and bile duct cancer. JAMA 1978;240:434–435.
  92. Bergquist A, Glaumann H, Persson B, Broome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case control study. Hepatology 1998;27:311–316.
  93. Mitacek EJ, Brunnemann KD, Hoffmann D, Limsila T, Suttajit M, Martin N, Caplan LS: Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: A risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis 1999;20:133–137.
  94. Brown DP: Mortality of workers exposed to polychlorinated biphenyls – An update. Arch Environ Health 1987;42:333–339.
  95. Szendroi M, Nemeth L, Vajta G: Asbestos bodies in a bile duct cancer after occupational exposure. Environ Res 1983;30:270–277.
  96. Sturm PD, Baas IO, Clement MJ, Nakeeb A, Offerhaus GJ, Hruban RH, Pitt HA: Alterations of the p53 tumor suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high incidence area. Int J Cancer 1998;78:695–698.
  97. Gilbert ES, Koshurnikova NA, Sokolnikov M, Khokhryakov VF, Miller S, Preston DL, Romanov SA, Shilnikova NS, Suslova KG, Vostrotin VV: Liver cancers in Mayak workers. Radiat Res 2000;154:246–252.
  98. Sharp GB: The relationship between internally deposited alpha-particle radiation and subsite-specific liver cancer and liver cirrhosis: An analysis of published data. J Radiat Res 2002;43:371–380.
  99. Van Kaick G, Dalheimer A, Hornik S, Kaul A, Liebermann D, Luhrs H, Spiethoff A, Wegener K, Wesch H: The German thorotrast study: Recent results and assessment of risks. Radiat Res 1999;152:S64–S71.
  100. Rubel LR, Ishak KG: Thorotrast-associated cholangiocarcinoma: An epidemiologic and clinicopathologic study. Cancer 1982;50:1408–1415.
  101. Kim KH, Kim CD, Lee HS, Lee SJ, Jeen YT, Chun JH, Song CW, Lee SW, Um SH, Choi JH, Ryu HS, Hyun JH: Biliary papillary hyperplasia with clonorchiasis resembling cholangiocarcinoma. Am J Gastroenterol 1999;94:514–517.
  102. Tesana S, Takahashi Y, Sithithaworn P, Ando K, Tenruyo S, Yutanawiboonchai W, Pairojkul C, Ruangjirachuporn W: Ultrastructural and immunohistochemical analysis of cholangiocarcinoma in immunized Syrian golden hamsters infected with O. viverrini and administered dimethylnitrosamine. Parasitol Int 2000;49:239–251.

    External Resources

  103. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Kanjanapitak A, Varavithya W, Phuapradit P, Bunyaratvej S, Upatham ES, Brockelman WY: Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology 1985;89:151–156.
  104. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002;89:962–970.
  105. Kim YT, Byun JS, Kim J, Jang YH, Lee WJ, Ryu JK, Kim SW, Yoon YB, Kim CY: Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003;50:8–12.
  106. Strong RW, Chew SP, Wall DR, Fawcett J, Lynch SV. Liver transplantation for hepatolithiasis. Asian J Surg 2002;25:180–182.
  107. Su CH, Shyr YM, Lui WY, P’Eng FK: Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997;84:959–973.
  108. Lesurtel M, Regimbeau JM, Farges O, Colombat M, Sauvanet A, Belghiti J: Intrahepatic cholangiocarcinoma and hepatolithiasis: An unusual association in Western countries. Eur J Gastroenterol Hepatol 2002;14:1025–1027.
  109. Kubo S, Kinoshita H, Hirohashi K, Hamba H: Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995;639–641.
  110. Chapman RW: Risk factors for biliary tract carcinogenesis. Ann Oncol 1999;10:308–311.

    External Resources

  111. Lipsett PA, Pitt HA, Colombani PM, et al: Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994;220:644–652.
  112. Bergquist A, Tribukait B, Glaumann H, Broome U: Can DNA cytometry be used for evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis? J Hepatol 2000;33:873–877.
  113. Johnson KJ, Olliff JF, Oliff SP: The presence and significance of lymphadenopathy detected by CT in primary sclerosing cholangitis. Br J Radiol 1998;71:1279–1282.
  114. Gores GJ: Early detection and treatment of cholangiocarcinoma. Liver Transplant 2000;6:S30–S34.

    External Resources

  115. Kaya M, de Groen P, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, Haddock MG, Lindor KD: Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: The Mayo Clinic experience. Am J Gastroenterol 2001;96:1164–1169.
  116. Fleming KA, Boberg KM, Glaumann H, Bergquist A, Smith D, Clausen OP: Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2001;34:360–365.
  117. Harrison PM: Prevention of bile duct cancer in primary sclerosing cholangitis. Ann Oncol 1999;10:S208–S211.

    External Resources

  118. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991;100:1710–1707.
  119. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, Prytz H, Sandberg-Gertzen H, Wallerstedt S, Lindberg G: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996;38:610–615.
  120. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJJ, LaRusso NF: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991;213:21–25.
  121. Green A, Uttaravichien T, Bhudhisawasdi V, Chartbanchachai W, Elkins DB, Marleng EO, et al: Cholangiocarcinoma in northeast Thailand. A hospital-based study. Trop Geogr Med 1991;43:193–198.
  122. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E: Increasing incidence of cholangiocarcinoma in Crete 1992–2000. Anticancer Res 2002;22:3637–3641.
  123. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC: Changing international trends in mortality rates for liver, biliary, pancreatic tumours. J Hepatol 2002;37:806–813.
  124. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, Khan SA, Elliott P, Thomas HC: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 2001;48:816–820.
  125. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357.
  126. American Cancer Society Cancer Facts and Figures: Available at: www.cancer.org 2003.
  127. Stewart HL, Lieber MM, Morgan DR: Carcinoma of the extrahepatic bile ducts. Arch Surg 1940;41:662–713.
  128. Renshaw K: Malignant neoplasms of the extrahepatic biliary ducts. Ann Surg 1922;76:205–221.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50